JP2018511609A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511609A5
JP2018511609A5 JP2017551276A JP2017551276A JP2018511609A5 JP 2018511609 A5 JP2018511609 A5 JP 2018511609A5 JP 2017551276 A JP2017551276 A JP 2017551276A JP 2017551276 A JP2017551276 A JP 2017551276A JP 2018511609 A5 JP2018511609 A5 JP 2018511609A5
Authority
JP
Japan
Prior art keywords
antibody
binding fragment
antigen
administration
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017551276A
Other languages
English (en)
Japanese (ja)
Other versions
JP6944375B2 (ja
JP2018511609A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024624 external-priority patent/WO2016160756A2/en
Publication of JP2018511609A publication Critical patent/JP2018511609A/ja
Publication of JP2018511609A5 publication Critical patent/JP2018511609A5/ja
Application granted granted Critical
Publication of JP6944375B2 publication Critical patent/JP6944375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017551276A 2015-03-31 2016-03-29 発作性夜間血色素尿症(pnh)患者の亜集団の同定および処置 Active JP6944375B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140711P 2015-03-31 2015-03-31
US62/140,711 2015-03-31
PCT/US2016/024624 WO2016160756A2 (en) 2015-03-31 2016-03-29 Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents

Publications (3)

Publication Number Publication Date
JP2018511609A JP2018511609A (ja) 2018-04-26
JP2018511609A5 true JP2018511609A5 (https=) 2019-05-09
JP6944375B2 JP6944375B2 (ja) 2021-10-06

Family

ID=55702135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017551276A Active JP6944375B2 (ja) 2015-03-31 2016-03-29 発作性夜間血色素尿症(pnh)患者の亜集団の同定および処置

Country Status (4)

Country Link
US (1) US20190135903A1 (https=)
EP (1) EP3277715A2 (https=)
JP (1) JP6944375B2 (https=)
WO (1) WO2016160756A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. 難治性全身型重症筋無力症の処置のための方法
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
US11578137B2 (en) * 2017-03-06 2023-02-14 The Trustees Of The University Of Pennsylvania Anti-C5 antibodies and uses thereof
SI3658184T1 (sl) 2017-07-27 2024-01-31 Alexion Pharmaceuticals, Inc., Formulacije z visoko koncentracijo protiteles proti-C5
CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群(aHUS)の治療のための抗C5抗体の用量および投与
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
CA3111396A1 (en) 2018-09-06 2020-03-12 The Trustees Of The University Of Pennsylvania Humanized anti-c5 antibodies and uses thereof
CN112996561A (zh) * 2018-10-30 2021-06-18 亚力兄制药公司 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PL3167888T3 (pl) * 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
CA3216595A1 (en) * 2013-03-14 2014-10-02 Kevin Fitzgerald Complement component c5 irna compositions and methods of use thereof
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Similar Documents

Publication Publication Date Title
JP2018511609A5 (https=)
US12029788B2 (en) Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗pcsk9阻害抗体
JP2022141868A (ja) 心血管リスクを低減させる方法
AU2018306612B2 (en) High concentration anti-C5 antibody formulations
JP2012525128A5 (https=)
JP2022105625A5 (https=)
JP2010528047A5 (https=)
JP2020528894A5 (https=)
JP2013538796A5 (https=)
JP2011504872A5 (https=)
JP2017536414A5 (https=)
JP2018500014A5 (https=)
JP2021525718A5 (https=)
KR20210089214A (ko) 항-FcRn 항체를 이용한 그레이브스 안병증의 치료 방법
JP2016528247A5 (https=)
EA031436B1 (ru) Водная фармацевтическая композиция, содержащий ее предварительно заполненный шприц и применение композиции в лечении аутоиммунных заболеваний
CA3181026A1 (en) Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
JP2019520316A5 (https=)
JP2018529661A5 (https=)
KR20230044312A (ko) 보체 매개된 질환을 갖는 대상체의 염증성 시토카인 및 피로
JPWO2019023564A5 (https=)
JP2019521156A5 (https=)
JP2017524675A5 (https=)
JP2009538916A5 (https=)